FDA Brief

Warning letters Drugs

FDA warning letter to

The Body Bean, LLC

LowIssued Feb 6, 2023Posted Feb 7, 2023Center for Drug Evaluation and Research | CDER

FDA warns The Body Bean over unregistered, unlisted scented hand sanitizer for U.S. sale.

What happened

FDA found this by reviewing The Body Bean’s drug registration and listing information in its electronic system, not by an inspection. It found the firm was making a scented hand sanitizer for U.S. commercial distribution without registering its establishment or listing the drug. FDA had sent a letter on October 21, 2022 about the same issue, and the required data still had not been submitted.

What FDA found

  1. The firm did not register its establishment with FDA as required for making a drug for U.S. commercial distribution.

    Section 510 of the FD&C Act; 21 CFR 207.17(a)
  2. The firm did not list The Body Bean’s Hand Sanitizer - Scented with FDA at initial registration.

    Section 510(j) of the FD&C Act; 21 CFR 207.41(a)
  3. FDA calls the hand sanitizer misbranded (not properly listed with FDA) because the firm failed to list it.

    Section 502(o) of the FD&C Act, 21 U.S.C. 352(o)

What FDA wants

FDA tells the company to notify it in writing within 15 working days of steps taken to address the violations and prevent recurrence, with related documentation, or explain why corrective actions cannot be completed and when they will be.

Who should pay attention

  • hand sanitizer brands and distributors
  • contract manufacturers or repackagers of over-the-counter drug products
  • companies selling drug products online or at retail

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Suretec Innovations, LLC

    Suretec Innovations failed manufacturing quality rules for OTC sanitizing wipes and did not list a private-label wipe.

    High risk
  2. InvaDerm, Inc.

    FDA says InvaDerm, Inc. of Somerset, NJ, markets unapproved new drugs without FDA-approved applications.

    High risk
  3. Aeroflex Industria de Aerosol Ltda.

    Brazil OTC drug maker Aeroflex ignored FDA records requests, prompting possible approval holds and US shipment refusals.

    High risk
  4. NSE Products, Inc. DBA Nu Skin Enterprises, Inc.

    FDA warns NSE Products (Nu Skin) over incomplete drug listing data for AP-24 products and 61 inactivated listings.

    Low